Last updated on January 2019

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Brief description of study

This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) and evaluate the overall safety profile of idelalisib and the overall response rate (ORR) by Week 24.

Clinical Study Identifier: NCT02536300

Contact Investigators or Research Sites near you

Start Over

Gilead Study Team

Centre Hospitalier Regional et Univeritaire de Tours
Tours, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.